Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sexton

Showing results (611-620 of 634) with videos related to

Pageof 64
Sort By:
Cancer Research|February 12, 2009
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesisLaetitia Devy, Lili Huang, Laurent Naa, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
BJU International|December 11, 2024
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumourLuca Antonelli, Axel Heidenreich, Aditya Bagrodia, et al.
Nature Biotechnology|February 22, 2005
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversityRené Michael Hoet, Edward H Cohen, Rachel Baribault Kent, et al.
European Urology Focus|August 15, 2024
Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and ManagementSophia Y Chahine, Khalid Y Alkhatib, Gevorg Arakelyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual CancerLuca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.
The New England Journal of Medicine|February 23, 2017
Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisAleena Banerji, Paula Busse, Mustafa Shennak, et al.
World Journal of Urology|March 13, 2022
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibilityChristian D Fankhauser, Luca Afferi, Sean P Stroup, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Penile cancer: Clinical Practice Guidelines in OncologyPeter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.
NEJM Evidence|February 6, 2024
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder CancerKarim Chamie, Sam S Chang, Eugene Kramolowsky, et al.
Pageof 64

Showing results (611-620 of 634) with videos related to

Sort By:
Pageof 64
Cancer Research|February 12, 2009
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesisLaetitia Devy, Lili Huang, Laurent Naa, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
BJU International|December 11, 2024
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumourLuca Antonelli, Axel Heidenreich, Aditya Bagrodia, et al.
Nature Biotechnology|February 22, 2005
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversityRené Michael Hoet, Edward H Cohen, Rachel Baribault Kent, et al.
European Urology Focus|August 15, 2024
Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and ManagementSophia Y Chahine, Khalid Y Alkhatib, Gevorg Arakelyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual CancerLuca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.
The New England Journal of Medicine|February 23, 2017
Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisAleena Banerji, Paula Busse, Mustafa Shennak, et al.
World Journal of Urology|March 13, 2022
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibilityChristian D Fankhauser, Luca Afferi, Sean P Stroup, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Penile cancer: Clinical Practice Guidelines in OncologyPeter E Clark, Philippe E Spiess, Neeraj Agarwal, et al.
NEJM Evidence|February 6, 2024
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder CancerKarim Chamie, Sam S Chang, Eugene Kramolowsky, et al.
Pageof 64